Editing the immune response could make gene therapy more effective
How to Stymie Distribution of a Potentially Dangerous Vaccine
Too Little is not Enough
Novavax Pops 8% On Covid-19 Vaccine Data; Analyst Says Buy Amid Pullback
Sanofi, GSK launch trial for Covid-19 protein-based vaccine
COVID-19 impact survey yields unexpected findings for individuals with progressive MS
Plasmin could be the link between COVID-19 comorbidities and serious illness
Vanderbilt launches clinical trial of outpatient treatments for COVID-19
J&J Abandons Influenza A Treatment Program After Interim Analysis
A ‘Human’ Touch vs. COVID-19
Novavax Strikes Covid-19 Vaccine Deal With Canada As Investors Take Profits
Another Day, Another Record S&P High As Central Banks Fan Biggest Ever Bubble
NIH Attacks FDA Over 'Premature' Approval Of 'Trump-Backed' Convalescent Plasma
Medical Groups Can Fight Possibly Deadly COVID-19 Vaccine
Sanofi Says Kevzara Drug Fails To Meet Endpoints in Covid-19 Study
US Open – New month. No problem. Stocks rise, Oil and Gold thrive on dollar weakness
Catch RNA Splicing Errors to Envision Novel Correctives
Vir Bio and GSK Join the Race for a Covid-19 Monoclonal Antibody Therapy
Former FDA Commissioner Questions Hahn’s Covid-19 Vaccine Fast-Track Statement
FDA commissioner willing to fast-track Covid-19 vaccine: FT
US Passes 6 Million Confirmed Coronavirus Cases: Live Updates
Gilead’s Remdesivir Now Authorized For All Hospitalized Covid-19 Patients
3 Monster Growth Stocks That Still Have Room to Run
J&J to start mid-stage coronavirus vaccine trials in three European countries
VBI Vaccines' COVID-19 Vaccine Could Be a Game Changer, Says 5-Star Analyst
Russia, India Plan Partnership To Mass Produce Vaccine As Merkel Warns Germans COVID-19 Outbreak Will Worsen: Live Updates
Moderna's COVID-19 Vaccine Looks Promising, But Its Future Is Still Uncertain, Says J.P. Morgan
Antiviral used to treat cat coronavirus also works against SARS-CoV-2
Novavax CEO expects filing for Covid-19 vaccine approval in December
COVID-19 is causing a renaissance in the UK biotech sector, we must ensure it lasts